Stock listing
A419UB Stock Price, News, Filings & Events — Nektar Therapeutics
Selected listing: A419UB · LS · EUR · DE
This page tracks Nektar Therapeutics's A419UB:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A419UB:LS. A419UB:LS is the stock-level entry point for investors researching Nektar Therapeutics, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A419UB:LS
- Asset type
- Stock
- Market cap
- $2.53B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Nektar Therapeutics A419UB:LS stock context
This page tracks Nektar Therapeutics's A419UB:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A419UB:LS. A419UB:LS is the stock-level entry point for investors researching Nektar Therapeutics, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Nektar Therapeutics
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-...
August 25, 2026
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
August 13, 2026
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financia...
July 28, 2026
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderat...
July 21, 2026
Nektar Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2026
Research Nektar Therapeutics
Nektar Therapeutics investor report
Review AI stock analysis and investor report context for A419UB:LS.
Nektar Therapeutics company profile
View the public company page for Nektar Therapeutics on 6ix.
Nektar Therapeutics news
Read company news and market updates connected to Nektar Therapeutics.
Nektar Therapeutics investor events
Find investor webinars, events, and replay context for Nektar Therapeutics.
Alternate listings
NKTR:NASDAQ
US · USD
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
ITH0:GETTEX
DE · EUR
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
A419UB:LSX
DE · EUR
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
ITH0:TRADEGATE
DE · EUR
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
0UNL:LSE
GB · USD
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
NKTR:BMV
MX · MXN
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
NKTR:BIVA
MX · MXN
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
NKTR:BOATS
US · USD
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
NKTR:BX
CH · CHF
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
ITH0:DUS
DE · EUR
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
ITH0:FWB
DE · EUR
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.
ITH0:HAM
DE · EUR
Alternate listing for Nektar Therapeutics; the primary context on this page is A419UB:LS.